Eosinophils <2% | Eosinophils ≥2% | |||
FP | Placebo | FP | Placebo | |
Age years | 63.8±6.94# | 64.1±6.83¶ | 63.5±7.34+ | 63.2±7.74§ |
Male | 190 (72)# | 171 (71)¶ | 88 (82)+ | 102 (81)§ |
BMI kg·m−2 | 24.91±4.92# | 25.17±4.54¶ | 23.61±4.28+ | 24.50±4.84§ |
White | 260 (99)# | 241 (>99)¶ | 106 (>99)+ | 126 (100)§ |
Current smoker | 133 (51)# | 118 (49)¶ | 42 (39)+ | 60 (48)§ |
Smoking pack-years | 43.2±29.78ƒ | 43.6±35.58## | 47.2±30.11¶¶ | 42.7±28.65++ |
Pre-bronchodilator FEV1 L | 1.32±0.472§§ | 1.25±0.462ƒƒ | 1.24±0.444### | 1.31±0.496¶¶¶ |
Pre-bronchodilator FEV1 % pred | 47.3±15.31§§ | 45.5±14.90ƒƒ | 42.5±14.09### | 45.4±15.46¶¶¶ |
Post-bronchodilator FEV1 L | 1.45±0.485§§ | 1.37±0.470ƒƒ | 1.36±0.440### | 1.44±0.496¶¶¶ |
Post-bronchodilator FEV1 % pred | 51.8±15.25§§ | 49.9±14.79ƒƒ | 46.5±13.79### | 49.9±15.24¶¶¶ |
Reversibility to salbutamol % | 4.5±3.5§§ | 4.4±3.35ƒƒ | 4.1±3.46### | 4.5±3.52¶¶¶ |
Data are presented as mean±sd or n (%). BMI: body mass index; FEV1: forced expiratory volume in 1 s; % pred: % predicted. Numbers of patients in each analysis group differed depending on data availability. #: n=263; ¶: n=242; +: n=107; §: n=126; ƒ: n=251; ##: n=214; ¶¶: n=104; ++: n=119; §§: n=261; ƒƒ: n=240; ###: n=106; ¶¶¶: n=124.